Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open and Parallel Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Polysaccharide Vaccine Comparing Three Groups: 2 - 4 Year, 5 - 14 Year and 15 - 29 Year Old Ethiopians

NCT00994695 is registered in ClinicalTrials.gov with Armauer Hansen Research Institute, Ethiopia as lead sponsor.

NCT NCT00994695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00994695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open and Parallel Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Polysaccharide Vaccine Comparing Three Groups: 2 - 4 Year, 5 - 14 Year and 15 - 29 Year Old Ethiopians
Lead sponsor
Armauer Hansen Research Institute, Ethiopia
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2005
Completion date
November 30, 2007
Enrollment
412 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal meningitis